Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab extension in non-histaminergic angioedema with normal C1-INH
NCT04444895Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of lanadelumab in hereditary angioedema with normal C1 inhibitor (HAE-nC1INH), sponsored by Takeda. Started Feb 2021; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema with normal C1 inhibitor (HAE-nC1INH)
Beyond the preview
Go deeper on NCT04444895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444895.